202.1 Operators shall ensure customers are reminded to consult with their physician regarding any medical condition which could be exacerbated by body art procedures.

202.2 Operators shall conspicuously post a disclosure sign in the reception area that is legible, clearly visible, not obstructed by any item for viewing by customers.

202.3 The lettering on the sign shall be at least five millimeters (5 mm) high for the phrase “REQUIRED DISCLOSURE”. All capital letters shall be at least five millimeters (5 mm) high and all lower case letters shall be at least three millimeters (3 mm) high. The disclosure sign shall read as follows:

REQUIRED DISCLOSURE

The United States Food and Drug Administration has not approved any pigment color additive for injectable use as tattoo ink. There may be a risk of carcinogenic decomposition associated with certain pigments when the pigments are subsequently exposed to concentrated ultra-violet light or laser irradiation.

SOURCE: Final Rulemaking published at 64 DCR 13496 (December 29, 2017).